



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/70	A1	(11) International Publication Number: WO 95/26734 (43) International Publication Date: 12 October 1995 (12.10.95)
(21) International Application Number: PCT/US95/04047 (22) International Filing Date: 31 March 1995 (31.03.95) (30) Priority Data: 222,128 4 April 1994 (04.04.94) US 360,995 20 December 1994 (20.12.94) US (71)(72) Applicant and Inventor: FREEMAN, William, R. [US/US]; 2361 Lozana Road, Del Mar, CA 92014 (US). (74) Agent: SEIDMAN, Stephanie; Brown, Martin, Haller & McClain, 1660 Union Street, San Diego, CA 92101-2926 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE (57) Abstract Methods for treatment of conditions of abnormally increased intraocular pressure, particularly those caused by glaucoma, by administration of phosphonylmethoxyalkyl nucleoside analogs are provided. Compositions formulated and packaged for intraocular administration for use in the methods are also provided. Administration of the compound may be by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, or may be, when penetrating derivatives are used, by topical application to the eye. The degree of reduction in pressure is dosage-dependent, and significant reduction in pressure is obtained. A single injection can produce prolonged, and perhaps permanent, lowering of the intraocular pressure.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE

5 This application is a continuation-in-part of U.S. application Serial No. 08/360,995 to William Freeman, filed December 20, 1994, entitled *TREATMENT OF CONDITIONS OF ABNORMALLY INCREASED INTRA-OCULAR PRESSURE BY ADMINISTRATION OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDE ANALOGS AND RELATED NUCLEOSIDE*
10 *ANALOGS*, and is also a continuation-in-part of U.S. application Serial No. 08/222,128 to William Freeman, filed April 4, 1994, entitled *TREATMENT OF CONDITIONS OF ABNORMALLY INCREASED INTRAOCULAR PRESSURE BY ADMINISTRATION OF HPMPC AND RELATED PHOSPHONYLMETHOXYALKYLCYTOSINES*. The subject matter of
15 each of U.S. application Serial Nos. 08/360,995 and 08/222,128 is incorporated herein by reference thereto.

FIELD OF THE INVENTION

 The invention herein relates to the compositions for and treatment of glaucoma and other conditions of abnormally increased intraocular
20 pressure. More particularly, it relates to treatment by application of therapeutic compounds and compositions containing the compounds.

BACKGROUND OF THE INVENTION

Glaucoma

 Glaucoma, which is the leading cause of blindness in the United
25 States, is a group of diseases characterized by progressive atrophy of the optic nerve head leading to visual field loss, and, ultimately, blindness. Glaucoma is generally associated with elevated intraocular pressure, which is an important risk factor for visual field loss because it causes further damage to optic nerve fibers.

30 There are several types of glaucoma, including open and closed angle glaucoma, all involve the abnormal increase in intraocular

-2-

pressure, primarily by obstruction of the outflow of aqueous humor from the eye, or, less frequently, by over production of aqueous humor within the eye. The most prevalent type is primary open angle glaucoma in which the aqueous humor has free access to the irridocorneal angle, but
5 aqueous humor drainage is impaired. In contrast, in closed angle glaucoma, the irridocorneal angle is closed by the peripheral iris. The angle block can usually be corrected by surgery. Less prevalent types of glaucoma include secondary glaucomas related to inflammation, trauma and hemorrhage. Glaucoma in its various forms is widely described in
10 the literature: see, e.g., Leibrandt, ed. (1982) *Professional Guide to Diseases*, pp. 1203-1206 and Andreoli et al., eds. (1986) *Cecil: Essentials of Medicine*, pp. 690-691.

Therapeutic treatment of glaucoma is directed at reducing intraocular pressure. Because intraocular pressure is controlled by
15 aqueous humor dynamics, an understanding of the production and removal of aqueous humor from the eyeball provides insights into the causes of increased ocular pressure associated with glaucoma. Aqueous humor is similar in electrolyte composition to plasma, but has a lower protein content. The aqueous humor keeps the eyeball inflated,
20 supplies the nutritional needs of the vascular lens and cornea and washes away metabolites and toxic substances within the eye. The bulk of aqueous humor formation is the product of active cellular secretion by nonpigmented epithelial cells of the ciliary process from the active transport of solute, probably sodium, followed by the osmotic
25 flow of water from the plasma. The nonpigmented epithelial cells of the ciliary process are connected at their apical cell membranes by tight junctions. These cells and the nonfenestrated iris vessels form the blood/aqueous barrier through which blood-borne large molecules, including proteins, do not pass.

-3-

Intraocular pressure is a function of the difference between the rate at which aqueous humor enters and leaves eye. Aqueous humor enters the posterior chamber by three means: 1) active secretion by nonpigmented epithelial cells of the ciliary process; 2) ultrafiltration of blood plasma; and 3) diffusion. Newly formed aqueous humor flows from the posterial chamber around the lens and through the pupil into the anterior chamber; aqueous humor leaves the eye by passive bulk flow at the irridocorneal angle and uveoscleral outflow. Any change in 1), 2) or 3) will disturb aqueous humor dynamics and likely alter intraocular pressure.

Treatments for Glaucoma

Most treatments for glaucoma focus on reducing intraocular pressure. Treatment has involved administration of beta-blockers such as timolol to decrease aqueous humor production, epinephrine to lower intraocular pressure or diuretics such as acetazolamide to reduce aqueous production, or administration of miotic eyedrops such as pilocarpine to facilitate the outflow of aqueous humor. Acute forms of glaucoma may require peripheral iridectomy surgery to relieve pressure where drug therapy is ineffective and the patient's vision is at immediate risk. Other forms of treatment have included physical or thermal destruction ("cyclo-destruction") of the ciliary body of the eye, commonly by surgery or application of a laser beam, cryogenic fluid or high frequency ultrasound. Each of these methods of destruction is costly and unduly invasive.

There are many problems, however, in effectively treating glaucoma and with long term medicinal or surgical therapies. One problem is the difficulty in devising means to generate pharmacologically effective intraocular concentrations and to prevent extraocular side effects elicited by systemic administration. Many drugs are administered topically or locally. The amount of a drug that gets into the eye is,

-4-

however, only a small percentage of the topically applied dose because the tissues of the eye are protected from such substances by numerous mechanisms, including tear turnover, blinking, conjunctival absorption into systemic circulation, and a highly selective corneal barrier.

- 5 Also, there is a risk for developing an intolerance to medical therapy or laser therapy, so that a filtration operation for control of intraocular pressure may become necessary. Present surgical techniques to lower intraocular pressure, when medication fails to decrease fluid flow into the eye or to increase fluid outflow, include
- 10 procedures that permit fluid to drain from within the eye to extraocular sites by creating a fluid passageway between the anterior chamber of the eye and the potential supra-scleral/sub-Tenon's space, or, alternatively, into or through the Canal of Schlemm [see, e.g., U.S. Patent No. 4,846,172]. The most common operations for glaucoma are
- 15 glaucoma filtering operations, particularly trabeculectomy. These operations involve creation of a fistula between the subconjunctival space and the anterior chamber. This fistula can be made by creating a hole at the limbus by either cutting out a portion of the limbal tissues with either a scalpel blade or by burning with a cautery through the
- 20 subconjunctival space into the anterior chamber. Fluid then filters through the fistula and is either gradually absorbed by vessels within the conjunctiva or gradually filters through the conjunctival tissues to be extruded externally with the tears. In order for the surgery to be effective, the fistula must remain substantially unobstructed. These
- 25 drainage or filtering procedures, however, often fail by virtue of closure of the passageway resulting from the healing of the very wound created for gaining access to the surgical site. Failures most frequently result from scarring at the site of the incisions in the conjunctiva and th
- 30 tenon's capsule. The surgery fails immediately in at least 15% of patients, and long term in a much higher percentage. Presently, this

-5-


consequence of trabeculectomy, closure of the passageway, is treated with 5-fluorouracil and mitomycin C, which apparently prevent closure by inhibiting cellular proliferation. These drugs, however, are highly toxic and have undesirable side effects, including scleral melting.

- 5 In view of the limited number of treatment options, there is, therefore, a need to develop more effective treatments for glaucoma. Therefore, it is an object herein to provide compositions and methods for treatment of glaucoma.

SUMMARY OF THE INVENTION

- 10 Methods for lowering intraocular pressure by administration of compositions containing effective amounts of phosphonylmethoxyalkyl nucleoside analogs are provided. One aspect of this therapy method is the apparent ability of a single dosage or a series of lower dosage intraocular injections of the administered compound to provide
- 15 substantial and long lasting reduction in intraocular pressure. Relatively small reductions in pressure to reduction up to as much as 20 mm Hg or more can be obtained.

The nucleoside analogs have the formula (I):




in which:

- (i) R^1 is $\text{CH}_2(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{OH})(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{CH}_2)_n(\text{OH})$, $\text{CH}_2\text{OCH}(\text{R}^7)$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p\text{O}$ or $\text{O}(\text{CH}_2)_p\text{CH}(\text{R}^7)\text{O}$; R^2 is OH ; R^7 is H or CH_2OH ; n is 0-6, generally 1-6, preferably 1-3, more preferably 1 or 2, and most preferably 1; p is 0-3, preferably 0 or 1; and m is 0 to about 3, preferably 0 or 1; or
- (ii) R^1 , R^2 , n , m and p are defined as in (i), and R^1 and R^2 are
- 30 linked to form a cyclic ester group;

-6-

B is a pyrimidine or purine of represented by formula (II):



10

and is selected from pyrimidin-1-yl, pyrimidinyl-3-yl, purin-3-yl, purin-7-yl and purin-9-yl, or pharmaceutically acceptable salts or esters thereof. In particular, B is selected from pyrimidin-1-yl, pyrimidinyl-3-yl, purin-3-yl, purin-7-yl and purin-9-yl, or pharmaceutically acceptable salts or esters thereof, particularly, salts with alkali metals ammonia or amines, or prodrug derivatives or other derivatives thereof, particularly derivatives that penetrate the cornea when administered topically as eyedrops.

15

R³, R⁴, R⁵ and R⁶ are independently selected from NH₂, alkyl-amino, aminoalkyl, hydroxyalkyl, hydrazino, H, OH, SH, alkylthio, alkyl, alkoxy, alkoxyalkyl, halide, CH_{3-q}(hal)_q in which q is 1-3 and hal is a halide, preferably, fluoro, hydroxylamino, or other group selected so that the resulting nucleoside analog retains the ability to lower intraocular pressure. Alkyl and alkoxy groups are preferably lower alkyl, preferably containing 1-3 carbons, more preferably 1-2 and most preferably are methyl groups.

20

25

R³, R⁴, R⁵ are preferably H, NH₂, CH₃, CH₃CH₂, dimethylamino, halide, or OH. R⁶ is preferably H or halide.

Preferred compounds are the phosphonylmethoxyalkyl compounds in which:

30

(i) R¹ is (CH₂)_n, CH(OH)(CH₂)_n or CH(CH₂)_n(OH), R² is OH; n is 0-6, generally 1-6, preferably 1-3, more preferably 0 or 1, and most preferably m is 0; or

-7-

(ii) R^1 is defined as in (i), R^2 is -O-, and R^1 and R^2 are linked to form a cyclic ester group.

The method produces significant and long term lowering of intraocular pressure, preferably to a level that does not result in damage to the optic nerve associated with increased ocular pressure, more preferably to a pressure that is within the normal range of intraocular pressure or within a range of pressure that does not damage the optic nerve fiber or cause loss of visual field. In particular, methods for the treatment of glaucoma by administering an effective amount of compound of formula I for lowering intraocular pressure to a level that damage to optic nerve fibers and resultant visual loss does not occur are provided.

The compound of formula I is formulated, preferably as a free drug or, alternatively, encapsulated into liposomes or other long acting drug delivery systems, for administration to the aqueous humor, such as by intraocular injection, at a concentration that is effective for lowering intraocular pressure. The compounds can also be formulated for topical application to the cornea, such as in the form of eyedrops, if derivatives of the compounds are selected or designed to penetrate into the aqueous humor whereby contact with the ciliary body is effected.

The compounds are preferably formulated for single dosage administration such that amounts in the range of about 1-1000 μg , 10-200 μg , more preferably 10-50 μg and typically about 10-40 μg , or 10-20 μg are delivered in a volume of about 0.05 -0.150 ml, preferably 0.1 ml into the eye. Thus, compositions for the treatment of glaucoma formulated for single dosage administration that contain an effective amount, typically 10-100 μg , preferably about 10-40 μg , more preferably about 20-40 μg of a compound of formula I in a pharmaceutically acceptable carrier are provided.

-8-

The above dosages are specified with reference to (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC]. The amount of compound will be adjusted for molecular weight differences from HPMPC so that comparable amounts on a molar basis are used. The amount is also adjusted for any difference in potency as described herein. For example, HPMPA exhibits approximately 10-50% of the potency of HPMPC. Compounds of lower potency than HPMPC, particularly those with a relatively high therapeutic index, are desirable because they permit better incremental titration of the total dosage. As describe herein, the compounds are intended to be incrementally administered to achieve intraocular pressure that does not adversely impact on the field of vision.

The compounds may also be formulated for implantation into the anterior or posterior chamber, preferably the vitreous cavity, in sustained released formulations, such as adsorbed to biodegradable supports, including collagen sponges, or in liposomes. Sustained release formulations may be formulated for multiple dosage administration, so that during a selected period of time, such as a month or up to about a year, several dosages are administered. Thus, for example, liposomes may be prepared such that a total of about two to up to about five or more times the single dosage is administered in one injection.

In preferred embodiments, the composition is provided in a sealed sterile vial containing an amount of a compound of formula I, that upon intraocular administration will deliver 10-100 μg , preferably 10-40 μg , more preferably 10-20 μg of a compound of formula I in a volume of 0.100 ml. Typically, the vials will, thus, contain about 0.150 ml of the composition.

Also provided are kits for practice of the methods herein. The kits contain one or more containers, such as sealed vials, with sufficient composition for single dosage administration, and one or more needles,

-9-

such as self sealing 25-33 gauge needles, preferably 33 gauge or smaller needles, precisely calibrated syringes or other precisely calibrated delivery device, suitable for intravitreal injection.

Administration of the composition is preferably by intraocular injection, although other modes of administration may be effective, if the sufficient amount of the compound achieves contact with the vitreous cavity. Intraocular injection may be effected by intravitreal injection, aqueous humor injection or injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, or by topical application to the cornea, if a penetrating derivative of a compound is used. It is believed that a single injection or series of injections of lower dosages will be sufficient to produce prolonged, and perhaps permanent, lowering of the intraocular pressure. Typically, a relatively low dose 10 μ g to about 40 μ g, preferably more than about 20 μ g to about 40 μ g, is administered initially and intraocular pressure is monitored over a period of at least several days, typically about two or more weeks until it does not change. If the pressure is still elevated, an additional dose may be administered, and the pressure monitored as above until a sufficiently low pressure that will not cause any damage to the optic nerve fibers or result in loss of vision is achieved. In some cases, the initial series of treatments may be sufficient to achieve a permanent lowering of pressure. In other cases, additional injections may be required at infrequent intervals to sustain the lowered pressure. The amount of the compound administered may be varied by the physician to obtain the desired degree of pressure decrease. Caution should be used to avoid achieving a pressure that is lower than desired.

DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of

-10-

skill in the art to which this invention belongs. All patents and publications referred to herein are incorporated by reference.

As used herein an effective amount of a compound for treating glaucoma is an amount that is sufficient to ameliorate, or in some
5 manner reduce a symptom or stop progression of a condition, preferably by reducing intraocular pressure, associated with glaucoma. Such amount may be administered as a single dosage or may be administered according to a regimen, whereby it is effective. The amount may cure the glaucoma by permanently effecting a lowering of the intraocular
10 pressure to a level that does not cause damage to the optic nerve, but, typically, is administered in order to reduce intraocular pressure, thereby ameliorating any associated pathology or symptoms of the disease. Typically, repeated administration is required to achieve the desired reduction in pressure or to halt progression of the associated pathology.

15 As used herein, the adverse symptoms associated with elevated intraocular pressure is/are the damage to the optic nerve observed as cupping and/or loss of visual field. Cupping refers to an observable depression in the central area or paracentral area of the optic nerve.

As used herein, pharmaceutically acceptable salts, esters or other
20 derivatives of the compounds include any salts, esters or derivatives that may be readily prepared by those of skill in this art using known methods for such derivatization and that produce compounds that may be administered to animals or humans without substantial toxic effects and that either are pharmaceutically active or are prodrugs. For
25 example, hydroxy groups can be esterified or etherified.

As used herein, the IC_{50} refers to an amount, concentration or dosage of a particular compound that achieves a 50% inhibition of a maximal response, in this case reduction of intraocular pressure.

As used herein, EC_{50} refers to a dosage, concentration or amount
30 of a particular test compound that elicits a dose-dependent response at

-11-

50% of maximal expression of a particular response that is induced, provoked or potentiated by the particular test compound.

As used herein, treatment means any manner in which the symptoms or pathology of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, and particularly refers to decreases in intraocular pressure.

As used herein, amelioration of the symptoms of a particular disorder, in this instance amelioration of the progression of the physiological changes associated with glaucoma and/or reduction in intraocular pressure, by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition. In particular, any decrease in intraocular pressure that is sufficient to prevent, inhibit, delay or halt damage to the optic nerve as evidenced by changes in the structure of the nerve visible by ophthalmoscopy or instruments that show cupping in the optic nerve or by loss in the visual field, particularly in the periphery.

As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography [TLC], gel electrophoresis and high performance liquid chromatography [HPLC], used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound may, however, be a mixture of stereoisomers. In such

-12-

instances, further purification might increase the specific activity of the compound.

As used herein, biological activity refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures.

As used herein, pharmaceutical activity refers to the activity of the compounds herein to reduce intraocular pressure. For purposes herein, the activity of compounds in lowering intraocular pressure can be measured relative to the activity of HPMPC in the guinea pig model described below.

As used herein, a prodrug is a compound that, upon in vivo administration, is metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound. To produce a prodrug, the pharmaceutically active compound is modified such that the active compound will be regenerated by metabolic processes. The prodrug may be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. Prodrugs or derivatives of the compounds that permit penetration into the aqueous human when administered by topical application to the eye are of particular interest herein. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, once a pharmaceutically active compound is identified, those of skill in the pharmaceutical art generally can design prodrugs of the compound [see, e.g., Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392].

As used herein, dosages of the compounds will normally be stated herein on a microgram (μg) per milliliter (ml) administered or

-13-


$\mu\text{g}/\text{per milliliter}$ ($\mu\text{g}/\text{ml}$) of vitreous basis. The human eye has vitreous volume of approximately 4 ml; the guinea pig vitreous volume is approximately 0.25 ml. Unless otherwise noted, typically the volume administered to a human subject is 0.1 ml, and to the guinea pig is 0.05 ml.

- 5 As used herein, lower alkyl, lower alkenyl, and lower alkynyl refer to carbon chains having six or fewer carbon atoms in a chain, preferably three or fewer. In preferred embodiments of the compounds provided herein that include alkyl, alkenyl, or alkynyl portions, the compounds include lower alkyl, lower alkenyl, and lower alkynyl portions that have
10 three or fewer carbon atoms in a chain.

- As used herein, the abbreviations for any substituent groups, protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical
15 Nomenclature [see, (1972) Biochem. 11:1726].

A. Compounds

- Compositions formulated for single dosage local administration to the eye containing compounds of formula (I) and derivatives of
20 formula (I):




- 25 in which:

- (i) R^1 is $\text{CH}_2(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{OH})(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{CH}_2)_n(\text{OH})$, $\text{CH}_2\text{OCH}(\text{R}^7)$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p\text{O}$ or $\text{O}(\text{CH}_2)_p\text{CH}(\text{R}^7)\text{O}$; R^2 is OH or $\text{O}(\text{CH}_2)_r\text{H}$, preferably OH; R^7 is H or CH_2OH ;
30 n is 0-6, generally 1-6, preferably 1-3, more preferably 1 or 2, and most preferably 1; p is 0-3, preferably 0 or 1; r is 1-6, more preferably 1-3, most preferably 1 or 2; and m is 0 to about 3, preferably 0 or 1; or

-14-

(ii) R^1 , R^2 , n , m and p are defined as in (i), and R^1 and R^2 are linked to form a cyclic ester group;

B is represented by formula:



so that B is selected from pyrimidin-1-yl, pyrimidinyl-3-yl, purin-3-yl,
 15 purin-7-yl and purin-9-yl, or pharmaceutically acceptable salts or esters thereof, particularly, salts with alkali metals ammonia or amines, or other prodrug derivatives thereof, such as derivatives that penetrate the cornea to provide delivery to the aqueous cavity of the eye, are provided.

20 R^3 , R^4 , R^5 and R^6 are independently selected from NH_2 , alkyl-amino, aminoalkyl, hydroxyalkyl, hydrazino, H, OH, SH, alkylthio, alkyl, alkoxy, alkoxyalkyl, halide, $CH_3-q(hal)_q$ in which q is 1-3 and hal is a halide, preferably fluoro, hydroxylamino, or other group selected so that the resulting nucleoside analog retains the ability to lower intraocular
 25 pressure. Alkyl and alkoxy groups are preferably lower alkyl, preferably containing 1-3 carbons, more preferably 1-2 and most preferably are methyl groups.

R^3 , R^4 , R^5 and R^6 are independently selected from NH_2 ,
 alkylamino, aminoalkyl, hydroxyalkyl, hydrazino, H, OH, SH, alkylthio,
 30 alkyl, alkoxy, alkoxy alkyl, halide, $CH_3-q(hal)_q$ in which q is 1-3 and hal is a halide, preferably, fluoro, hydroxylamino, or other group selected so that the resulting nucleoside analog retains the ability to lower intraocular pressure. Alkyl and alkoxy groups are preferably lower alkyl,

-15-

preferably containing 1-3 carbons, more preferably 1-2 and most preferably are methyl groups.


R^3 , R^4 and R^5 are preferably independently selected from NH_2 , H, OH, lower alkylamino, CH_3 , $C(hal)_3$ in which hal is halide, particularly CF_3 or equivalent variations thereof. R^3 , R^4 , R^5 are more preferably H, NH_2 , dimethylamino, halide, or OH. R^6 is preferably H, CH_3 or halide, and more preferably H or halide, particularly bromo. R^3 , R^4 , R^5 and R^6 can be selected so that B is uridiny, thymidiny, cytosiny, or adeniny or derivatives thereof.

10 In more preferred embodiments the compounds are those in which R^1 and R^2 are (i) only, in which R^1 is $CH_2CH(OH)(CH_2)_n$, $CH_2CH(CH_2)_n(OH)$, $CH_2OCH(R^7)$, $CH_2OCH(R^7)(CH_2)_p$, $CH_2OCH(R^7)(CH_2)_pO$ or $O(CH_2)_pCH(R^7)O$; R^2 is OH or $O(CH_2)_rH$; R^7 is OH or $(CH_2)_mOH$, preferably $(CH_2)_mOH$; n is 0-6, preferably 0-3; r is 1-6, preferably 1-3, 15 more preferably 1; p is 0-3; and m is 0 to 3.

Most of the compounds will have an asymmetric carbon atom, such as when n is 1 and R^1 is other than methylene, and will exist in more than one enantiomeric form. In such instances, the preferred compounds are racemic mixtures (RS) or, preferably, are in the (S) form, 20 and are in the form of a free acid or salt thereof. Compounds of formula (I) that contain an a chiral center are preferred, and it is preferred that it is in the s configuration. Racemic mixtures are, however, acceptable.


Of the compounds of formula (I), those with the following formulae are of particular interest:

-16-




in which B, R⁷ and preferred embodiments of B, are defined as above.

Among other preferred compounds of formula (I) are those of formula (II):



in which:



n is 0-6, generally 1-6, preferably 1-3, more preferably 1 or 2, and most preferably 1; or

(ii) R¹ and R², which are as defined in (i), are linked to form a cyclic ester group;

in which B and preferred embodiments of B, are as defined above.

The compounds of formulae (I) and (II) for use in the methods herein include, but are not limited to, compounds in which B is selected from uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymine-1-yl, 5-
 30 fluorouracil-1-yl, uracil-3-yl, cytosin-3-yl, 5-methylcytosin-3-yl, thymine-3-yl, 5-fluorouracil-3-yl, guanine-9-yl, guanine-7-yl, guanine-3-yl, adenine-9-yl,

-17-

adenin-7-yl, adenin-3-yl, hypoxanthin-9-yl, hypoxanthin-7-yl, hypoxanthin-3-yl, 2-methyladenin-9-yl, 2-methyladenin-7-yl, 2-methyladenin-3-yl, 2-methylthioadenin-9-yl, 2-methylthioadenin-7-yl, 2-methylthioadenin-3-yl, 2-aminoadenin-9-yl, 2-aminoadenin-7-yl, 2-amino-adenin-3-yl, 2-
5 aminopurin-9-yl, 2-aminopurin-7-yl, 2-aminopurin-3-yl, N⁶-dimethyladenin-9-yl, N⁶-dimethyladenin-7-yl, N⁶-dimethyladenin-3-yl, 8-bromo-adenin-9-yl, 8-bromoadenin-7-yl, 8-bromoadenin-3-yl, 8-hydroxyadenin-9-yl, 8-hydroxyadenin-7-yl, 8-hydroxyadenin-3-yl, 6-hydroxylaminopurin-9-yl, 6-hydroxylaminopurin-7-yl, 6-hydroxylaminopurin-3-yl, 6-hydra-
10 zinopurin-9-yl, 6-hydrazinopurin-7-yl, 6-hydrazinopurin-3-yl, 6-thiopurin-9-yl, 6-thiopurin-7-yl, 6-thiopurin-3-yl, purin-9-yl, purin-7-yl, purin-3-yl, xanthin-9-yl, xanthin-7-yl, and xanthin-3-yl.

Preferred among these compounds are those in which B is uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymin-1-yl, 5-fluorouracil-1-yl, 15 guanin-9-yl, guanin-7-yl, adenin-3-yl, hypoxanthin-9-yl, 2-methyladenin-9-yl, 2-methylthioadenin-9-yl, 2-aminoadenin-9-yl, 2-aminopurin-9-yl, N⁶-dimethyladenin-9-yl, 8-bromoadenin-9-yl, 8-hydroxyadenin-9-yl, 6-hydroxylaminopurin-9-yl, 6-hydrazinopurin-9-yl, 6-thiopurin-9-yl, purin-9-yl, and xanthin-9-yl. Compounds in which B is cytosin-1-yl, uracil-1-yl, 5-
20 methylcytosin-1-yl, thymin-1-yl, and 5-fluorouracil-1-yl may be more preferred.

Other preferred compounds include, but are not limited to, the N-(2-phosphonylmethoxyethyl) [PME] and N-(3-hydroxy-2-phosphonylmethoxypropyl) [HPMP] pyrimidine and purine nucleoside analogs, particularly the pyrimidine analogs. HPMP analogs are presently generally
25 preferred and sHPMP analogs are presently more preferred.

In preferred compounds R¹ is a chiral center and is preferably in the *s* configuration. Some particularly preferred compounds include, but are not limited to: 9-(*s*)-(2-phosphonylmethoxy-3-hydroxy-
30 propyl)adenine [HPMPA], 9-(2-phosphonylmethoxyethyl)adenine [PMEA],

-18-

(s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC], (2-phosphonylmethoxyethyl)cytosine [PMEC], (2-phosphonylmethoxyethyl)guanine [PMEG], 1-(s)-3-hydroxy-2-phosphonylmethoxypropyluracil [(S)-HPMPU], 9-(s)-3-hydroxy-2-phosphonylmethoxypropyl-
5 guanine [(S)-HPMPG], (2-phosphonylmethoxyethyl)-2,6-diaminopurine [PMEDAP], and 9-(s)-2-phosphonylmethoxypropyladenine [(S)-PMPA].

The compounds cyclic (s)-3-hydroxy-2-phosphonylmethoxypropylcytosine [cHPMPC] and 9-(cyclic(s)-3-hydroxy-2-phosphonylmethoxypropyl)adenine [cHPMPA], are also among the preferred compounds.
10 The compounds 9-(r)-3-hydroxy-2-phosphonylmethoxypropyladenine [(R)-HPMPA], 9-(r)-2-phosphonylmethoxypropyladenine [(R)-PMPA] and 9-(2-phosphonylmethoxyethyl)adenine [PMEA] are also intended for use herein.

Among preferred compounds herein are: 9-(s)-(2-phosphonylmethoxy-3-hydroxy-propyl)adenine [HPMPA] and (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC].
15

B. Preparation and selection of compounds

1. Preparation

Some of the compounds provided herein are compounds that are
20 available for use antiviral agents [see, e.g., U.S. Patent Nos. 5,142,051 and 4,724,233; see, also U.S. Patent Nos. 4,605,658, and 4,230,708 and De Clercq et al. (1991) Biochemical Pharmacology 42:963-972] and, thus, may be obtained from commercial sources or synthesized by known methods [see, e.g., U.S. Patent Nos. 5,142,051 and
25 4,724,233]. Novel compounds of formulae (I) and (II) may be prepared by modification of the procedures for preparation of the known compounds. Such modification is within the level of skill of the art of synthetic organic chemistry.

Use of and formulation of the compounds for lowering intraocular
30 pressure has not heretofore been described. Anti-virally effective

-19-

dosages, if administered to the eye, would necessarily be lower than dosages for lowering intraocular pressure in order to avoid permanently reducing intraocular pressure in subjects that do not have elevated intraocular pressure or glaucoma.

5 **2. Selection of compounds**

The compounds of formulae (I) and (II) can be selected on the basis of their activity in the guinea pig model. For example, injection of HPMPC, cHPMPC or HPMPA into the vitreous cavity of the guinea pig eye, results in a decrease intraocular pressure that parallels decreases in
10 human eyes. The results appear to be directly extrapolatable to effective dosages in humans. Normal intraocular pressure in the guinea pig, which is very similar to humans, is a median of 14.7 mm Hg, and the normal range is between about 10 mm to about 22 mm. Among these compounds HPMPC causes the largest drop in IOP/ μ g adminis-
15 tered; and cHPMPC causes the least drop. All compounds that show activity in this model, however, should be useful, since it is desirable for treatment to be effected by administering a series of administrations of the compound in order to avoid lowering IOP too much.

Histologic studies of the guinea pigs show changes in the
20 structure of the ciliary body that would be expected to lower aqueous secretion. Optical properties of the compound when injected into the vitreous cavity were assessed by indirect ophthalmoscopy and fundus photography, as well as by observing the behavioral characteristics of the animals who underwent intravitreal injection. In all cases, the
25 optical pathways were normal, as was animal visual behavior, indicating that the compound does not obstruct or affect the visual pathways in any way. This indicates that the intravitreal injection of the compound as described should result in no adverse effects and will have a major therapeutic effect.

-20-

In the guinea pig model, injections are performed with anesthetized animals and baseline intraocular pressures are taken for comparison with post injection pressures. Manometric measure of intraocular pressure are performed by placing a 33 gauge cannula into the anterior of the guinea pig eye and determining the pressure by manometry using a pressure transducer and recording apparatus. Injection, via the limbus, of 0.05 ml compositions containing 2 μg , 10 μg , 50 μg , 80 μg , 100 μg and 250 μg of HPMPC (per 0.25 ml vitreous) resulted in decreases in pressure, indicative of a dose-response relationship in the range of about 10-200 $\mu\text{g}/0.25$ ml vitreous in this model. The results were parallel, though higher in concentrations, to results observed in humans in which the dose response curve is linear in the range of about 10 μg up to about 80-100 μg injected per 4 ml of vitreous in the human eye. Multiple doses of HPMPC in the this model also showed a clear dose response.

Injection of 250 μg HPMPC (about 1 mg/ml vitreous) in this model results in a substantial drop in intraocular pressure that ultimately reached zero within several days. The effect appears to be approximately equivalent to administration of about 100 μg (25 $\mu\text{g}/\text{ml}$ vitreous) to a human eye. A 50 μg (200 $\mu\text{g}/\text{cc}$) injection to guinea pig lowers the pressure by approximately 30-60% (to lower than 10 mm Hg) without adverse effects. This is equivalent to about 20-40 μg injected into the human eye. A dose of HPMPC of 6.25 μg caused minimal to no drop in IOP; and a dose of 156 μg causes a similar, slightly increased, drop in IOP. Administration of 500 μg resulted in an IOP of zero.

In humans, administration of 10-20 μg of HPMPC causes a drop of about 2-4 mm Hg, and repeated injections every six weeks causes further lowering of IOP. At doses of 40 μg , there is a larger drop, and at 100 μg the IOP drops to zero.

-21-

Injection of cHPMPC at dose equivalents to HPMPC of 500 μ g lowered IOP gradually from the normal range to between 2 and 6 mm Hg over the course of 4 weeks. Doses of 156 μ g (HPMPC equivalent) had no effect. This indicates that cHPMPC is a very mild
5 pressure lowering agent, and, thus, will permit gradual lowering of IOP to the normal range at a useful dosage range (dosages in the range of 100 μ g to 400 μ g).

HPMPA, which has also been tested in this model, appears to be about 10 to 50% less potent than HPMPC, and appears have a higher
10 therapeutic index dose (therapeutic index = dosage required reduce the pressure zero/dosage to drop to 10%) than HPMPC. HPMPA, will, thus, also be suitable for therapeutic use for treating glaucoma, since it will permit precise titration of the appropriate total dosage to achieve the desired decrease in pressure.

15 Other compounds of formulae (I) and (II) are assessed for intraocular pressure lowering activity in this model. Compounds that exhibit intraocular pressure lowering activity substantially similar to HPMPC or with greater specific activity than HPMPC in this model are preferred for use herein. Compounds that are less potent, but exhibit
20 specific activity that is approximately at least about 30-50% of HPMPC are also suitable for use. As long as the activity is sufficient for a therapeutically effective dose (equivalent in activity to about 10 μ g of HPMPC) to be delivered to a human eye in about 0.100 ml, a selected compound is suitable for use herein. Thus, any compound that exhibits
25 detectable IOP-lowering activity in this model should be suitable for use herein.

C. Formulation

Compositions containing therapeutically effective for low ring intraocular pressure amounts of the compounds of formula (I) are
30 provided herein. The compounds are formulated in concentrations

-22-

suitable for single dosage administration by intraocular administration in an amount that incrementally lowers intraocular pressure from an elevated level to a level that is sufficiently low to avoid the damaging effects of elevated intraocular pressure. Typically the concentrations of compounds are between about 10% and 50%, preferably greater than about 20% and up to about 40% weight/volume. The compositions are preferably formulated for intraocular, preferably intravitreal administration, such that injection of about 0.100 ml delivers about 10 μ g to less than about 100 μ g, preferably about 10 μ g to about 40 μ g or 50 μ g. Presently, compositions formulated for single dosage administration of about 40 μ g in a volume of 0.1 ml are preferred.

To prepare compositions, one or more compounds of formula (I) or (II) are mixed with a suitable ophthalmologically acceptable carrier. Upon mixing or addition of the compound(s), the resulting mixture may be a solution, suspension, emulsion or the like. In addition, the compounds may be formulated as the sole pharmaceutically active ingredient in the composition or may be combined with other active ingredients, particularly anti-glaucoma agents, or pharmaceutically inactive ingredients.

Of the compounds of formulae (I) and (II), those that are polar and highly water soluble are well suited to ocular use, especially where intraocular injection is the preferred method of administration. If necessary, however, pharmaceutically acceptable salts or other derivatives of the conjugates may be prepared. If the resultant mixture is amenable to filtration, it can be filter sterilized using nylon 66 matrix 0.22 μ m sterile syringe filter systems that cause no ocular toxicity.

The active compound is included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined

-23-

empirically by testing the compounds in known in vitro and in vivo systems, particularly the guinea pig model described herein. Based upon a comparison of the activity of a particular compound in this model with compounds, such as HPMPC, that are exemplified herein, compositions
5 containing effective amounts of the selected compound are prepared. Typically, a therapeutically effective dosage, upon single dosage administration, should reduce intraocular pressure by an amount less than 20 mm Hg, preferably less than 10 mm Hg, and on the order of a 10%-30% decrease, depending upon the initial pressure. This may be
10 repeated, typically after an interval of at least 14 days or more, until intraocular pressure is sufficiently reduced to a level at which the optic nerve damage and visual field loss is halted or the rate of damage or loss reduced, preferably substantially reduced.

The compositions are formulated in an ophthalmologically
15 acceptable carrier for intraocular, preferably intravitreal, administration in a volume of between about 0.05 ml and 0.150 ml, preferably about 0.05 and 0.100 ml, containing between about 1-1000 μ g, preferably, 10 μ g to less than about 100 μ g, more preferably about 10-50 μ g, and more preferably about 20-40 μ g of a compound of formula (I) or (II).
20 Thus, the compositions contain between about 10% and 50% (weight/volume), with about 25% or 30% to 40-50% preferred, of a compound of formula (I) or (II).

For administration by intraocular injection or via eyedrops, suitable carriers include, but are not limited to, physiological saline, phosphate
25 buffered saline (PBS), balanced salt solution (BSS), lactate Ringers solution, and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof. Liposomal suspensions may also be suitable as pharmaceutically acceptable carriers. These may be prepared according
30 to methods known to those skilled in the art. Suitable

-24-

ophthalmologically acceptable carriers are known. Solutions or mixtures intended for ophthalmic use may be formulated as 0.01% - 10% isotonic solutions, pH about 5-7, with appropriate salts [see, e.g., U.S. Patent No. 5,116,868, which describes typical compositions of

5 ophthalmic irrigation solutions and solutions for local application]. Such solutions, which have a pH adjusted to about 7.4, contain, for example, 90-100 mM sodium chloride, 4-6 mM dibasic potassium phosphate, 4-6 mM dibasic sodium phosphate, 8-12 mM sodium citrate, 0.5-1.5 mM magnesium chloride, 1.5-2.5 mM calcium chloride, 15-25 mM sodium

10 acetate, 10-20 mM D.L.-sodium β -hydroxybutyrate and 5-5.5 mM glucose.

The compounds of formulae (I) and (II) may be prepared with carriers that protect them against rapid elimination from the body, such as time release formulations or coatings. Such carriers include

15 controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and other types of implants that may be placed directly into the anterior or posterior chamber or vitreous

20 cavity of the eye. The compositions may also be administered in pellets, such as Elvax pellets (ethylene-vinyl acetate copolymer resin).

Liposomal suspensions, including tissue-targeted liposomes, may also be suitable as pharmaceutically acceptable carriers. For example, liposome formulations may be prepared by methods known to those of skill in the art [see, e.g., Kimm et al. (1983) Bioch. Bioph. Acta 728:339-398; Assil et al. (1987) Arch Ophthalmol. 105:400; and U.S. Patent No. 4,522,811]. The nucleoside analogs provided herein may be encapsulated into the aqueous phase of liposome systems. HPMPC has been encapsulated into liposomes using a modification of the method of

25 Kimm et al. and described in EXAMPLE 4.

30

-25-

The active materials can also be mixed with other active materials, that do not impair the desired action, or with materials that supplement the desired action or have other action, including viscoelastic materials, such as hyaluronic acid, which is sold under the trademark HEALON, which is a solution of a high molecular weight (MW) of about 3 millions fraction of sodium hyaluronate [manufactured by Pharmacia, Inc; see, e.g., U.S. Patent Nos. 5,292,362, 5,282,851, 5,273,056, 5,229,127, 4,517,295 and 4,328,803], VISCOAT [fluorine-containing (meth)acrylates, such as, 1H,1H,2H,2H-hepta-decafluorodecylmethacrylate; see, e.g., U.S. Patent Nos. 5,278,126, 5,273,751 and 5,214,080; commercially available from Alcon Surgical, Inc.], ORCOLON [see, e.g., U.S. Patent No. 5,273,056; commercially available from Optical Radiation Corporation], methylcellulose, methyl hyaluronate, polyacrylamide and polymethacrylamide [see, e.g., U.S. Patent No. 5,273,751]. The viscoelastic materials are present generally in amounts ranging from about 0.5 to 5.0%, preferably 1 to 3% by weight of the conjugate material and serve to coat and protect the treated tissues. The compositions may also include a dye, such as methylene blue or other inert dye, so that the composition can be seen when injected into the eye. Additional anti-glaucoma or intravitreal pressure-lowering agents, including beta-blockers, such as epinephrine, and diuretics such as acetazolamide, or pilocarpine, also may be included.

The compositions can be enclosed in ampules, disposable syringes or multiple or single dose vials made of glass, plastic or other suitable material. Such enclosed compositions can be provided in kits. In particular, kits containing vials, ampules or other container, preferably disposable vials with sufficient amount of the composition to deliver about 0.100 ml thereof, and disposable needles, preferably self sealing 25-30 gauge needles, are provided herein. Prepackaged vials of

-26-

compositions, containing concentrations of compounds of about 10 $\mu\text{g}/0.100\text{ ml}$, 20 $\mu\text{g}/0.100\text{ ml}$, 25 $\mu\text{g}/0.100\text{ ml}$, 30 $\mu\text{g}/0.100\text{ ml}$, 35 $\mu\text{g}/0.100\text{ ml}$ p to about 100 $\mu\text{g}/0.100\text{ ml}$ in 5 or 10 $\mu\text{g}/0.100\text{ ml}$ increments, with sufficient volume, typically 0.125-0.150 mls, to deliver 5 0.100 mls are provided. For treatment of elevated intraocular pressure compositions in the range greater than about 20 $\mu\text{g}/0.100\text{ ml}$ and less than about 80 $\mu\text{g}/0.100\text{ ml}$, preferably, about 40 $\mu\text{g}/0.100\text{ ml}$ are preferred.

Finally, the compounds may be packaged as articles of 10 manufacture containing packaging material, typically a vial, an ophthalmologically acceptable composition containing a compound of formula (I) or (II) provided herein, which is effective for lowering intraocular pressure, and a label that indicates that the compound or salt thereof is used for lowering intraocular pressure.

15 D. Administration

The compositions containing the compounds are administered intraocularly or by other means, such as topically in the form of penetrating eyedrops, whereby contact of the compounds with the aqueous humor is effected. Intraocular administration may be effected 20 by intravitreal injection, aqueous humor injection, injection into the external layers of the eye, such as subconjunctival injection or subtenon injection, preferably in free form, but, alternatively, in liposomes or other sustained drug delivery device. Administration of the compound is preferably by intravitreal injection, preferably through self sealing 25-30 gauge needles or other suitably calibrated delivery device. Injection into the eye may be through the pars plana via the self-sealing needle.

Without being bound by any theory regarding the mechanism of this extended or possibly permanent period of efficacy for the treatment of glaucoma contact of the compounds provided her in with the ciliary 30 body decreases the ability of the ciliary body of the eye to secrete

-27-

aqueous humor. Since the ciliary body is preferably accessed by intravitreal injection or by aqueous humor injection, such modes of administration are presently preferred. Administration by other modes that ultimately result in decreased intraocular pressure, such as injection
5 into the external layers of the eye, such as subconjunctival injection or subtenon injection, or topical application to the cornea in a form that penetrates into the eye, can be employed. Such modes of administration should be designed to result in introduction of a compound within the aqueous or vitreous fluids, thereby providing
10 access to the ciliary body.

The routes of administration, especially by injection, are specialized and unique and the properties of the compound that render it highly suitable for this use include its lack of toxicity (other than to decrease aqueous secretion), high intraocular therapeutic index, optical
15 clarity, which precludes it from adversely affecting the vision of the eye to which it is administered, and its high water solubility which allows extremely small volumes to be injected under topical or local anesthetics into the mid-vitreous cavity of the human eye.

Typically, in order to avoid excessive lowering of intraocular
20 pressure, the compounds are administered in incremental dosages, generally more than about 20 μg up to about 40 or 50 μg /injection, depending upon the starting pressure and observed optic nerve fiber and visual field changes. The dosage should be selected based upon the initial starting pressure and observed symptoms, and carefully selected
25 to achieve a resulting pressure that is within normal range of 8-22 mm Hg. It appears that in many cases, a single intravitreal injection may be sufficient to obtain permanent reduction. Care should, however, be taken to avoid achieving to large a reduction in pressure. Cons -
quently, incremental doses may be preferred.

-28-

After administration of a single injection, intraocular pressure is monitored for one to three weeks, and, if necessary, a second dose of the composition is administered, followed by one to three weeks of monitoring. This is repeated until the desired, generally, although not necessarily within the range of 8-22 mm Hg, intraocular pressure is attained. It is understood that there are variations in the range of normal pressure. Consequently, for glaucoma patients, elevated pressure is determined by the pressure and evidence of optic nerve damage as evidenced visually, by a decrease in the visual field or other test indicative of such damage.

In glaucoma patients, intraocular pressures are typically above 18-20 mm Hg, but in some patients, the loss of visual field and optic nerve changes are observed at pressures in the range of 15-22 mm Hg. Such glaucoma is referred to as low tension glaucoma. Also, in some patients, the changes in visual field and the optic nerve do not occur until the pressure is as high as 30-33 mm Hg. In either case, the treatment is designed to effect a lowering of intraocular pressure, whereby the adverse symptoms are halted or their progress slowed. Effectiveness of treatment can be assessed by observing a decrease in pressure, whatever the pressure was before treatment, and a concomitant halting or slowing of damage to the optic nerve and visual field loss.

Thus, the absolute amount of pressure change, and ultimately, number of doses and dosage of the compounds herein, must be determined with reference to each patient. Desirably, the lowest total dosage that effects treatment, as defined herein, should be administered. Therefore, small incremental doses, typically about 20-60 μg , preferably 20-40 μg or about 50 μg per injection (0.100 ml injected), depending upon the intraocular pressure and observed changes in the optic nerve and visual field loss, are administered. Lower

-29-

dosages, as low as about 10 μg , 20 μg or 30 μg , may be administered when the initial pressure is within, or close to, normal range. Presently, dosages on the order of about 40 μg (35-45 μg) per injection appear to be preferred.

5 The patient is thereafter periodically monitored, and, if intraocular pressure increased, additional dose(s) is (are) administered. Where the reduction in pressure is not permanent, it is expected that further injections will be required only on an infrequent basis, since the intraocular pressure lowering effects of these compounds are long term
10 and possibly permanent.

 It is further understood that, for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and
15 that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed methods or concentrations of active compounds in the claimed compositions. It is also understood that the concentrations of the compounds are specified in weight/volume with reference to HPMPD and that the compounds of
20 formula (I) or (II) vary in molecular weight and potency compared to HPMPD. Adjustments in amounts for molecular weight differences and potency differences from HPMPD are intended to be encompassed herein. Thus, if a compound exhibits 50% of the activity of HPMPD in the guinea pig model set forth herein, it is understood that the range of
25 concentrations, expressed as μg , will be approximately twice the ranges set forth for HPMPD. Also, if the molecular weight differs by about 2% or more, the concentrations will be corrected accordingly.

 The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

-30-

EXAMPLE 1**Intravitreal injection of 10 μ g-100 μ g HPMPC**

Twenty subjects having relatively normal or reduced intraocular pressure, but suffering from cytomegalovirus (CMV) retinitis associated with HIV infection, were injected into the vitreous cavity with HPMPC in an amount of 10-100 μ g in total volume of 0.1 ml. It is noted that individuals infected with HIV that have AIDS exhibit reduced intraocular pressure; thus, the absolute values of the pressures observed in these subjects must be viewed in this context.

The pressure lowering effect began within 3-14 days and was observed to be long lasting. The degree of pressure reduction was a function of the dosage, with the lowest dosages (~ 10 μ g/ml) producing relatively small amounts of pressure reduction, the largest (~ 100 μ g/ml) producing the maximum reduction (in some cases down to essentially 0 mm Hg), and the intermediate dosages producing intermediate degrees of pressure reduction.

EXAMPLE 2**Intravitreal injection of 20 μ g HPMPC**

The effects of injection of 0.100 ml (sterile saline) containing of 20 μ g HPMPC in a consecutive series of 38 eyes of AIDS patients infected with CMV were assessed. Intraocular pressure was measured by applanation tonometry at baseline, weeks 2 and weeks 4-6 after each injection. The analysis was performed on a series of 95 injections and pairs of means were compared utilizing the Tukey-Kramer technique [JMP software, SAS Institute, Carey, NC], which corrects for multiple comparisons.

Twenty-six patients (52 eyes) were studied at baseline, 38 eyes received 1 injection, 16 eyes received 2 injections, and 7 eyes received 3 injections. The mean intraocular pressure at baseline was 9.82; two weeks after the first injection it was 7.31, and at 4-6 weeks, it was

-31-

8.29. Two weeks after the second injection, the mean intraocular pressure was 6, and after 4-6 weeks it was 7.25. Two weeks after the third injection, mean intraocular pressure was 7.14, and after 4-6 weeks it was 8. Tukey-Kramer HSD analysis [JMP software, SAS Institute, Carey, NC], revealed that the difference between baseline pressure and pressure two weeks after the first injection, the difference between baseline and the pressure two weeks after the second injection, and the difference between baseline and the pressure at the 4-6 weeks after the second injection were statistically significant.

10

EXAMPLE 3**Effect of 40 μ g intravitreal injection of HPMPC on intraocular pressure**

HPMPC (40 μ g in 0.100 ml) was injected into test subjects who were CMV-infected AIDS patients. Three eyes of three patients have been injected with 40 μ g of HPMPC. All eyes had initial pressures in the low normal range typical of AIDS patients. In one eye, the initial pressure was 14; it was 12 on day 7 and 9 on days 35 and 31. In the second eye in the second patient, the initial pressure was 10 and was 3 on day 11 and 2 on day 46. The pressure in the treated eye of the third patient was initially 10. After injection, it was 4 on day 11, and 5 on day 24; vision remained good.

These results, as well as those in Examples 1 and 2, indicate that the drop in intraocular pressure is long in duration and may be permanent. Further, comparisons of the results achieved with 40 μ g injections compared to 20 μ g, 10 μ g, and 100 μ g injections indicate that there is a dose related effect on intraocular pressure.

-32-

EXAMPLE 4**Preparation of liposome encapsulated HPMPC**

A chloroform lipid mixture was prepared by dissolving dimyristoyl glycerol (1.5 mg), triolein (1.68 mg) and cholesterol (5.81 mg) dissolved
5 in 1 ml of chloroform in a vial. HPMPC (1 mg/ml sucrose solution) was dissolved in 200 mmol sucrose, pH 6.8. One ml of this solution was added dropwise to a vial containing the chloroform lipid mixture. The vial was tightly sealed and vortexed for 6 min to produce spherules of HPMPC droplets coated with a lipid monolayer floating in a pool of
10 chloroform and excess lipids. One ml of this mixture was added rapidly to each of two vials containing 2.5 ml glucose (240 mmol/liter), and the suspension was vortexed for four seconds. The resulting liposomes were then dried by passing nitrogen over them (8 liters per minute) in a flask containing 250 mmol per liter of sucrose until no detectable
15 chloroform remained. The mixture was centrifuged at 400 x G for 10 min, the supernatant was removed and the pellet of liposomes was resuspended in 0.9 % sodium chloride solution and recentrifuged. This wash step was repeated 5 times in order to remove any unencapsulated HPMPC.

20 Drug release studies were performed in triplicate at 37° C as follows. The liposomes were suspended in phosphate buffered saline in a 30 ml syringe mounted on a revolving rotor. At designated time intervals, 3 ml aliquots were removed and centrifuged. The resulting supernatants were withdrawn, the pelleted liposomes were disrupted
25 by freezing and resuspending in 1 ml distilled water and the concentration of HPMPC determined by HPLC and/or ultraviolet absorption at 254 nm. Spectrophotometric analyses were performed by diluting the samples with chloroform-methanol (2:3 v/v) and the concentration determined by comparison with a standard curve.

-33-


The liposomes are injected in the same manner that free drug is injected, except that a slightly larger gauge needle (25-27 gauge) may be needed, and the HPMPC is slowly released from the liposomes over weeks to months, thereby providing gradual decrease in pressure and
5 possibly, if higher dosages are administered, avoiding the need for additional injections. The efficacy period of the encapsulated HPMPC appears to be between about 170 and 240 days.

Since modifications will be apparent to those of skill in this art, it
10 is intended that this invention be limited only by the scope of the appended claims.

-34-

THAT WHICH IS CLAIMED:

1. Use of a compound of formula (I) or pharmaceutically acceptable salts thereof for formulation as a medicament for reducing intraocular pressure, wherein formula (I) is:



in which:

R^1 and R^2 are (i) or (ii) as follows:

(i) R^1 is $\text{CH}_2(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{OH})(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{CH}_2)_n(\text{OH})$, $\text{CH}_2\text{OCH}(\text{R}^7)$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p\text{O}$ or

15 $\text{O}(\text{CH}_2)_p\text{CH}(\text{R}^7)\text{O}$;

R^2 is OH or $\text{O}(\text{CH}_2)_r\text{H}$;

R^7 is OH or $(\text{CH}_2)_r\text{OH}$, preferably $(\text{CH}_2)\text{OH}$;

n is 0-6, preferably 0-3;

r is 1-6, preferably 1-3, more preferably 1;


20 p is 0-3; and

m is 0 to 3; or

(ii) R^1 , R^2 , n , m , r and p are defined as in (i), and R^1 and R^2 are linked to form a cyclic ester group;

B is a pyrimidine or purine of formula (II):

25




-35-

and is selected from among pyrimidin-1-yl, pyrimidinyl-3-yl, purin-3-yl, purin-7-yl and purin-9-yl;

- R^3 , R^4 , R^5 and R^6 are independently selected from NH_2 , alkylamino, aminoalkyl, hydroxyalkyl, hydrazino, H, OH, SH, alkylthio, alkyl, alkoxy, alkoxyalkyl, halide, hydroxylamino $CH_3-q(hal)_q$ in which m is 1-3 and hal is a halide.

2. The use of claim 1, wherein the compound is selected from



3. The use of claim 1, wherein:

R^1 is $CH_2CH(OH)(CH_2)_n$, $CH_2CH(CH_2)_n(OH)$, $CH_2OCH(R^7)$, $CH_2OCH(R^7)(CH_2)_p$, $CH_2OCH(R^7)(CH_2)_pO$ or $O(CH_2)_pCH(R^7)O$;

25 R^2 is OH or $O(CH_2)_rH$;

R^7 is OH or $(CH_2)_rOH$, preferably $(CH_2)OH$;

n is 0-6, preferably 0-3;

r is 1-6, preferably 1-3, more preferably 1;


p is 0-3; and

30 m is 0 to 3.

4. The use of claim 1, wherein the compound has formula (III):


-36-

5



wherein R^1 and R^2 are selected from (i) or (ii):

10



(ii) R^1 and R^2 , which are as defined in (i), are linked to form a cyclic ester group.

15

5. The use of any of claims 1-4, wherein n is 1-3, preferably 1, p is 0 or 1, r is 1 and m is 0 or 1.

6. The use of any of claims 1-5, wherein R^3 , R^4 , R^5 are each independently selected from H, NH_2 , CH_3 , CH_3CH_2 , CF_3 , dimethylamino, halide, and OH, preferably NH_2 , H, OH, CH_3 and halide and R^6 is H or halide, preferably H.

7. The use of any of claims 1-6, wherein B is selected from among uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymine-1-yl, 5-fluorouracil-1-yl, uracil-3-yl, cytosin-3-yl, 5-methylcytosin-3-yl, thymine-3-yl, 5-fluorouracil-3-yl, guanine-9-yl, guanine-7-yl, guanine-3-yl, adenine-9-yl, adenine-7-yl, adenine-3-yl, hypoxanthine-9-yl, hypoxanthine-7-yl, hypoxanthine-3-yl, 2-methyladenine-9-yl, 2-methyladenine-7-yl, 2-methyladenine-3-yl, 2-methylthioadenine-9-yl, 2-methylthioadenine-7-yl, 2-methylthioadenine-3-yl, 2-aminoadenine-9-yl, 2-aminoadenine-7-yl, 2-aminoadenine-3-yl, 2-aminopurine-9-yl, 2-aminopurine-7-yl, 2-aminopurine-3-yl, N^6 -dimethyladenine-9-yl, N^6 -dimethyladenine-7-yl, N^6 -dimethyladenine-3-yl, 8-bromoadenine-9-yl, 8-bromoadenine-7-yl, 8-bromoadenine-3-yl, 8-hydroxyadenine-9-yl, 8-hydroxyadenine-7-yl, 8-hydroxyadenine-3-yl, 6-hydroxylaminopurine-9-yl, 6-hydroxylaminopurine-7-yl, 6-hydroxylaminopurine-3-yl, 6-hydrazinopurine-9-yl, 6-hydrazinopurine-7-yl, 6-hydrazinopurine-3-yl, 6-

-37-

thiopurin-9-yl, 6-thiopurin-7-yl, 6-thiopurin-3-yl, purin-9-yl, purin-7-yl, purin-3-yl, xanthin-9-yl, xanthin-7-yl, and xanthin-3-yl.

8. The use of claim 7, wherein B is selected from the group consisting of uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymine-1-yl, 5-fluorouracil-1-yl, guanine-9-yl, guanine-7-yl, adenine-3-yl, hypoxanthine-9-yl, 2-methyladenine-9-yl, 2-methylthioadenine-9-yl, 2-aminoadenine-9-yl, 2-aminopurine-9-yl, N⁶-dimethyladenine-9-yl, 8-bromoadenine-9-yl, 8-hydroxyadenine-9-yl, 6-hydroxylaminopurine-9-yl, 6-hydrazinopurine-9-yl, 6-thiopurine-9-yl, purine-9-yl, and xanthine-9-yl.

9. The use of claim 7, wherein B is selected from the group consisting of adenine-9-yl, cytosine-1-yl, uracil-1-yl, 5-methylcytosine-1-yl, thymine-1-yl, and 5-fluorouracil-1-yl.

10. The use of any of claims 1-9, wherein the compound is selected from among 9-(s)-(2-phosphonylmethoxy-3-hydroxy-propyl)-adenine (HPMPA), 9-(2-phosphonylmethoxyethyl)adenine (PMEA), cyclic (s)-3-hydroxy-2-phosphonylmethoxypropylcytosine (cHPMPC), (2-phosphonylmethoxyethyl)cytosine (PMEC), (2-phosphonylmethoxyethyl)-guanine (PMEG), 1-(s)-3-hydroxy-2-phosphonylmethoxypropyluracil ((S)-HPMPU), 9-(s)-3-hydroxy-2-phosphonylmethoxypropylguanine ((S)-HPMPG) (2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP), and 9-(s)-2-phosphonylmethoxypropyladenine ((S)-PMPA).

11. The use of any of claims 1-9, wherein the compound is (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and the amount delivered by a single dosage of the medicament is greater than about 20 μ g up to about 50 μ g.

12. The use of any of claims 1-9, wherein the compound is 9-(s)-(2-phosphonylmethoxy-3-hydroxy-propyl)adenine (HPMPA), and the amount delivered by a single dosage of the medicament is greater than about 40 μ g up to about 500 μ g.


-38-

13. The use of any of claims 1-12, wherein the compound is formulated for intravitreal administration.

14. The use of any of claims 1-12, wherein the compound is formulated for administration by aqueous humor injection, by injection
5 into the external layers of the eye, or topically, whereby contact with the vitreous cavity is effected.

15. The use of any of claims 1-12, wherein the compound is formulated for intraocular administration.

16. A composition, comprising an effective amount of a
10 compound of formula I in an ophthalmologically acceptable carrier:



wherein:

R^1 and R^2 are (i) or (ii) as follows:

(i) R^1 is $\text{CH}_2(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{OH})(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{CH}_2)_n(\text{OH})$,
20 $\text{CH}_2\text{OCH}(\text{R}^7)$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p\text{O}$ or
 $\text{O}(\text{CH}_2)_p\text{CH}(\text{R}^7)\text{O}$;

R^2 is OH or $\text{O}(\text{CH}_2)_r\text{H}$;

R^7 is OH or $(\text{CH}_2)_r\text{OH}$, preferably $(\text{CH}_2)\text{OH}$;

n is 0-6, preferably 0-3;

25 r is 1-6, preferably 1-3, more preferably 1;


p is 0-3; and

m is 0 to 3; or

(ii) R^1 , R^2 , n , m , r and p are defined as in (i), and R^1 and R^2
are linked to form a cyclic ester group;

30 B is a pyrimidine or purine of formula (II):

-39-




10

and is selected from the group consisting of pyrimidin-1-yl, pyrimidinyl-3-yl, purin-3-yl, purin-7-yl and purin-9-yl;

R^3 , R^4 , R^5 and R^6 are independently selected from NH_2 , alkylamino, aminoalkyl, hydroxyalkyl, hydrazino, H, OH, SH, alkylthio, 15 alkyl, alkoxy, alkoxyalkyl, halide, hydroxylamino $CH_{3-q}(hal)_q$ in which m is 1-3 and hal is a halide; and

the composition is formulated for single dosage intraocular administration of the effective amount; and the amount is effective for reducing intraocular pressure, whereby the progression of the adverse 20 symptoms associated with elevated intraocular pressure is halted or slowed.

17. The composition of claim 16, wherein the compound is selected from among



-40-

18. The composition of claim 16, wherein:

R^1 and R^2 are selected from (i) only, and

R^1 is $\text{CH}_2\text{CH}(\text{OH})(\text{CH}_2)_n$, $\text{CH}_2\text{CH}(\text{CH}_2)_n(\text{OH})$, $\text{CH}_2\text{OCH}(\text{R}^7)$,
 $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p$, $\text{CH}_2\text{OCH}(\text{R}^7)(\text{CH}_2)_p\text{O}$ or $\text{O}(\text{CH}_2)_p\text{CH}(\text{R}^7)\text{O}$;

5 R^2 is OH or $\text{O}(\text{CH}_2)_r\text{H}$;

R^7 is OH or $(\text{CH}_2)_r\text{OH}$, preferably $(\text{CH}_2)\text{OH}$;


n is 0-6, preferably 0-3;

r is 1-6, preferably 1-3, more preferably 1;


p is 0-3; and

10 m is 0 to 3.

19. The composition of claim 17, wherein the compound has
 formula (III):



wherein:



and R^2 is OH.

25

20. The composition of any of claims 16-19, wherein n is 1-3,
 preferably 1, p is 0 or 1, r is 1 and m is 0 or 1.

21. The composition of any of claims 16-20, wherein R^3 , R^4 , R^5
 are each independently selected from H, NH_2 , CH_3 , CH_3CH_2 , CF_3 ,
 30 dimethylamino, halide, and OH, preferably NH_2 , H, OH, CH_3 and halide
 and R^6 is H or halide, preferably H.

22. The composition of any of claims 16-21, wherein R^3 , R^4
 and R^5 are each independently selected from NH_2 , H, OH, CH_3 , halide
 and R^6 is H.

-41-

23. The composition of any of claims 16-21, wherein B is selected from among uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymine-1-yl, 5-fluorouracil-1-yl, uracil-3-yl, cytosin-3-yl, 5-methylcytosin-3-yl, thymine-3-yl, 5-fluorouracil-3-yl, guanine-9-yl, guanine-7-yl, guanine-3-yl, adenine-9-yl, adenine-7-yl, adenine-3-yl, hypoxanthine-9-yl, hypoxanthine-7-yl, hypoxanthine-3-yl, 2-methyladenine-9-yl, 2-methyladenine-7-yl, 2-methyladenine-3-yl, 2-methylthioadenine-9-yl, 2-methylthioadenine-7-yl, 2-methylthioadenine-3-yl, 2-aminoadenine-9-yl, 2-aminoadenine-7-yl, 2-aminoadenine-3-yl, 2-aminopurine-9-yl, 2-aminopurine-7-yl, 2-aminopurine-3-yl, N⁶-dimethyladenine-9-yl, N⁶-dimethyladenine-7-yl, N⁶-dimethyladenine-3-yl, 8-bromoadenine-9-yl, 8-bromoadenine-7-yl, 8-bromoadenine-3-yl, 8-hydroxyadenine-9-yl, 8-hydroxyadenine-7-yl, 8-hydroxyadenine-3-yl, 6-hydroxylaminopurine-9-yl, 6-hydroxylaminopurine-7-yl, 6-hydroxylaminopurine-3-yl, 6-hydrazinopurine-9-yl, 6-hydrazinopurine-7-yl, 6-hydrazinopurine-3-yl, 6-thiopurine-9-yl, 6-thiopurine-7-yl, 6-thiopurine-3-yl, purine-9-yl, purine-7-yl, purine-3-yl, xanthine-9-yl, xanthine-7-yl, and xanthine-3-yl.

24. The composition of any of claims 16-23, wherein B is selected from the group consisting of uracil-1-yl, cytosin-1-yl, 5-methylcytosin-1-yl, thymine-1-yl, 5-fluorouracil-1-yl, guanine-9-yl, guanine-7-yl, adenine-3-yl, hypoxanthine-9-yl, 2-methyladenine-9-yl, 2-methylthioadenine-9-yl, 2-aminoadenine-9-yl, 2-aminopurine-9-yl, N⁶-dimethyladenine-9-yl, 8-bromoadenine-9-yl, 8-hydroxyadenine-9-yl, 6-hydroxylaminopurine-9-yl, 6-hydrazinopurine-9-yl, 6-thiopurine-9-yl, purine-9-yl, and xanthine-9-yl.

25. The composition of any of claims 16-23, wherein B is selected from the group consisting of cytosin-1-yl, uracil-1-yl, 5-methylcytosin-1-yl, thymine-1-yl, and 5-fluorouracil-1-yl.

26. The composition of any of claims 16-21, wherein B is a purine.

-42-

27. The composition of claim 16, wherein the compound is selected from the group consisting of 9-(s)-(2-phosphonylmethoxy-3-hydroxy-propyl)adenine (HPMPA).

28. The composition of claim 16, wherein the compound is 1-
5 (s)-3-hydroxy-2-phosphonylmethoxypropyluracil ((S)-HPMPU), 9-(s)-3-hydroxy-2-phosphonylmethoxypropylguanine ((S)-HPMPG) or 9-(s)-3-hydroxy-2-phosphonylmethoxypropylguanine ((S)-HPMPG).

29. The composition of claim 16, wherein the compound is selected from 9-(2-phosphonylmethoxyethyl)adenine (PMEA), cyclic (s)-
10 3-hydroxy-2-phosphonylmethoxypropylcytosine (cHPMPC), (2-phosphonylmethoxyethyl)cytosine (PMEC), (2-phosphonylmethoxyethyl)-guanine (PMEG), 9-(cyclic(s)-3-hydroxy-2-phosphonylmethoxypropyl)-adenine (cHPMPA), (2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP), and 9-(s)-2-phosphonylmethoxypropyladenine ((S)-PMPA).

15 30. The composition of any of claims 16-29, wherein the concentration of the compound is about 10 μg to about 50 μg per 0.100 ml of the composition.

31. The composition of claim 28, wherein the concentration of the compound is about 20 μg to about 500 μg per 0.100 ml of the
20 composition.

32. The composition of any of claims 16-29, wherein the concentration of the compound is greater than about 20 μg up to about 40 μg per 0.100 ml of the composition.

33. The composition of claim 16, wherein the compound is (s)-
25 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and the amount is greater than about 20 μg up to about 50 μg per 0.100 ml of the composition.

34. Use of a composition of any of claims 16-33 as a medicament for reducing intraocular pressure.

-43-

35. A kit, comprising a container containing an amount of a composition of any of claims 16-33 sufficient to deliver a volume of about 0.100 ml; a syringe for delivering the volume; and, optionally, a needle for use with the syringe for intraocular injection of the volume.

5 36. A kit, comprising a disposable syringe containing an about 0.100 ml of a composition of any of claims 16-33 for intravitreal administration; and a needle for use with the syringe for intravitreal injection.

37. An article of manufacture, comprising packaging material and a composition of any of claims 16-33 contained within the
10 packaging material, wherein the composition is formulated for application to the eye; and the packaging material includes a label that indicates that the compound is used for lowering intraocular pressure.

38. A method for reducing intraocular pressure, comprising administering to the eye an effective amount of a composition of any of
15 claims 16-33

39. The method of claim 38, wherein the compound is (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and the amount is greater than about 20 μ g up to about 50 μ g.

40. The method of claim 38, wherein the compound is 9-(s)-(2-
20 phosphonylmethoxy-3-hydroxy-propyl)adenine (HPMPA).

41. The method of claim 38, wherein the compound is cyclic (s)-3-hydroxy-2-phosphonylmethoxypropylcytosine (cHPMPC) or 9-(cyclic(s)-3-hydroxy-2-phosphonylmethoxypropyl)adenine (cHPMPA).

42. The method of any of claims 38-41 wherein the amount is
25 about 20 μ g up to about 100 μ g.

43. The method of any of claims 38-41, wherein the compound is administered intravitreally.

44. The method of any of claims 38-41, wherein the compound is administered by aqueous humor injection, by injection into the

-44-

external layers of the eye, or topically, whereby contact with the vitreous cavity is effected.

45. The method of any of claims 38-43, wherein the initial intraocular pressure has damaged the optic nerve or reduced the visual field; and the method further comprises, monitoring intraocular pressure after the injection, and then, when the pressure stabilizes, injecting another effective amount of the compound; and repeating the monitoring and injecting step a plurality of times until intraocular pressure is at a level whereby further damage to the optic nerve or loss of visual field does not occur.

PCT/US 95/04047

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP-A-0 253 412 (REGA FOUNDATION) 20 January 1988 cited in the application see page 3, line 33-55 ---	16-33, 35-37
A	US-A-5 039 797 (YALE UNIVERSITY) 13 August 1991 see the whole document ---	1-45
X	THE JOURNAL OF INFECTIOUS DISEASES, vol. 169, no. 3, March 1994 pages 642-647, FLORES-AGUILAR, M. ET AL 'LONG-ACTING THERAPY OF VIRAL RETINITIS WITH (S)-1-(3-HYDROXY-2-PHOSPHONOMETHOXYPROPYL) CYTOSINE' see the whole document --- -/--	16-25, 31,35-37

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 July 1995

Date of mailing of the international search report

01.08.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Mair, J

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 33, no. 5, April 1992 pages 1557-1563, DOLNAK, D. R. ET AL 'LACK OF RETINAL TOXICITY OF THE ANTICYTOMEGALOVIRUS DRUG (S)-1-(3-HYDROXY-2-PHOSPHONOMETHOXYPROPYL) CYTOSINE' see the whole document ---	16-33, 35-37
X	ANTIVIRAL RESEARCH, vol. 16, no. 1, July 1991 pages 93-100, MAUDGAL, P.C. ET AL 'EFFECTS OF PHOSPHONYLMETHOXYALKYL-PURINE AND PYRIMIDINE DERIVATIVES ON TK+ AND TK- HSV-1 KERATITIS IN RABBITS' see the whole document -----	16-27, 29-33, 35-37

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/04047

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Reark: Although claims 28-45 are directed towards a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-253412	20-01-88	AU-B- 600002	02-08-90
		AU-A- 7575987	21-01-88
		IE-B- 60117	01-06-94
		JP-A- 63045289	26-02-88
		KR-B- 9504179	27-04-95
		US-A- 5142051	25-08-92
<hr/>			
US-A-5039797	13-08-91	NONE	
<hr/>			